Sutent and Nexavar Put Brakes on Renal-Cell Carcinoma

Article

NEW YORK -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.

NEW YORK, Jan. 10 -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.

Sutent more than doubled progression-free survival (P

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Real-World Weight Loss With GLP-1s Falls Short of Trial Results: Daily Dose / image credit: ©New Africa/AdobeStock

Real-World Weight Loss With GLP-1s Falls Short of Trial Results: Daily Dose

Sydney Jennings
July 4th 2025
Article

Your daily dose of the clinical news you may have missed.

The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment

The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment

Sydney Jennings
June 11th 2025
Podcast

Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.

Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression / image credit ©martialred/stock.adobe.com

Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression

Grace Halsey
July 2nd 2025
Article

Depression and anxiety affect as many as 1 in 4 people with AD, with pruritis, sleep disorders, education level, and comorbidities identified as independent risk factors.

The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship

The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship

Sydney Jennings
June 4th 2025
Podcast

Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.

FDA Backs Shield Test for Broad Early Cancer Screening: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Backs Shield Test for Broad Early Cancer Screening: Daily Dose

Sydney Jennings
July 2nd 2025
Article

Your daily dose of the clinical news you may have missed.

Phase 2b study of Psychedelic Compound BPL-003 Shows Rapid, Persistent, and Significant Improvement in Treatment Resistant Depression / image credit ©fyb/stock.adobe.com

Phase 2b Study of Psychedelic BPL-003 Shows Rapid, Persistent, and Significant Improvement in Treatment Resistant Depression

Grace Halsey
July 2nd 2025
Article

A single dose of BPL-003 was associated with improved MADRS scores as early as day 2 that were durable through week 8; phase 3 planning is anticipated.

© 2025 MJH Life Sciences

All rights reserved.